India business contributes to a stellar performance
Aditya Puri former MD of HDFC bank joins Solara board as chairman
Nureca Ltd has reported financial results for the period ended June 30, 2021.
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
A total quantum of more than 4.39 crore doses was also available for direct procurement by the states as well as private hospitals in the month of May 2021
Subscribe To Our Newsletter & Stay Updated
